Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. (EPRX) generates a steady flow of news as a clinical-stage biotechnology company advancing drug candidates built on its Diffusphere™ drug delivery platform. Company updates focus on clinical data readouts, trial progress, financing events, and operational developments tied to its lead programs in eosinophilic esophagitis (EoE) and osteoarthritis.
A central theme in Eupraxia’s news is the RESOLVE trial for EP-104GI in EoE. Press releases detail Phase 1b/2a dose-escalation results, including tissue health outcomes measured by the EoE Histological Scoring System, symptom improvements via the Straumann Dysphagia Index, durability of response out to 52 weeks after a single administration, and safety and tolerability observations such as the absence of reported Serious Adverse Events and candidiasis in disclosed cohorts. Additional news covers the transition into and expansion of the randomized, placebo-controlled Phase 2b portion of RESOLVE and plans to increase patient numbers and dose levels.
Investors following EPRX news will also see pipeline and platform updates, including references to EP-104IAR for knee osteoarthritis and Eupraxia’s broader pipeline of long-acting formulations for inflammatory joint indications, oncology, and other potential disease areas. Financing announcements, such as public offerings of common shares under Canadian and U.S. prospectuses, provide context on how the company funds its clinical and preclinical programs, regulatory submissions, and manufacturing scale-up.
This news feed brings together clinical trial milestones, financial results, capital markets transactions, and conference participation disclosed by Eupraxia. Readers can use it to track how EP-104GI and EP-104IAR progress through development, how the Diffusphere™ platform is being applied across indications, and how management describes risk factors, cash runway, and strategic priorities over time.
Leviathan Metals (OTC:LVXFF) agreed to sell the Timor Gold Project (EL006278) in Victoria, Australia to Au Gold Corp in exchange for CAD$75,000 cash (CAD$10,000 on signing, CAD$65,000 on closing) and 5,000,000 Au Gold shares, representing 11.16% ownership of Au Gold as of Jan 16, 2026. Timor covers 116.45 km2 and hosts historic high‑grade workings including Leviathan Mine (documented production 181,000 tonnes for 67,511 oz at 11.4 g/t Au).
The MPSA includes contingent cash consideration of $3.00 per ounce for any JORC or NI 43‑101 resources disclosed, payable within 90 days of public disclosure. Closing is subject to TSX Venture Exchange approval. Separately, Leviathan entered a marketing services agreement for C$260,000 through Oct 31, 2026 with optional renewals.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive tissue health and symptom data from the ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis. At 12 weeks the highest-dose cohort (8mg/site, 20 sites, n=3) showed near-complete tissue normalization (EoEHSS Grade -0.57 [94%], Stage -0.63 [97%]). Patients in 4mg/site cohorts (n=9) maintained 12-week improvements at 36 weeks (Grade -0.22, Stage -0.24). Among patients with ≥60% esophagus treated, clinical remission was 58% at 12 weeks (n=19), 79% at 24 weeks (n=14), and 67% at 52 weeks (n=6). Safety: >200 patient-months in 31 patients with no SAEs and no oral candidiasis reported.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported additional 52-week follow-up data from the Phase 1b/2a RESOLVE trial of a single administration of EP-104GI for eosinophilic esophagitis (EoE) on Nov 13, 2025.
Cohort 6 (n=3) showed durable symptom response at 52 weeks: all three maintained clinical benefit and two remained in clinical remission; combined Cohorts 5 and 6 had 4 of 6 patients in remission at 52 weeks. Week-36 remission across Cohorts 5–7 was 67% (n=9). Across >200 patient-months there were no serious adverse events and no oral or GI candidiasis. Plasma fluticasone levels remained predictable and well below typical daily asthma inhaler levels.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q3 2025 results and a business update on Nov 4, 2025. Key items: 52-week durable symptom and tissue responses observed after a single EP-104GI treatment (two-thirds of Cohort 5, N=3 remained in remission at 1 year).
The company closed an $80.5 million public offering (14,636,363 shares at $5.50) and held $89.0 million cash as of Sept 30, 2025, with a stated runway into the first half of 2028. Topline Phase 2b RESOLVE data expected by Q3 2026.
Operational notes: net loss of $6.4M for Q3 2025; management is monitoring potential impacts from proposed U.S.-Canada tariffs on supply chain and costs.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive clinical data from Cohort 9 of the RESOLVE trial for EP-104GI in Eosinophilic Esophagitis, testing the highest dose of 8mg per injection. The results showed significant improvements in tissue health outcomes and eosinophil reduction, with patients experiencing rapid clinical remission and maintaining long-term benefits.
Based on these promising results, the company plans to expand the Phase 2b portion of RESOLVE from 60 to at least 120 patients. The trial will use 8mg per injection with 20 injections per administration. Additionally, Eupraxia intends to broaden EP-104GI's development program by initiating trials for additional GI indications in H1 2026, including potential applications in fibrostenotic Crohn's, benign esophageal strictures, and Barrett's esophagus prevention.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has successfully closed its public offering of 14,636,363 common shares at US$5.50 per share, raising approximately US$80.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares.
The company plans to use the proceeds to advance its product pipeline, particularly the development of EP-104GI for eosinophilic esophagitis and its upcoming Phase 2b clinical readout. The funding is expected to extend the company's capital runway into the first quarter of 2028. Cantor and LifeSci Capital served as joint book-running managers, with Bloom Burton acting as co-manager for the offering.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced the pricing of its public offering of 12,727,273 common shares at US$5.50 per share, aiming to raise approximately US$70 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to an additional 1,909,090 shares under the same terms.
The offering, expected to close on September 24, 2025, is being managed by Cantor and LifeSci Capital as joint book-running managers, with Bloom Burton as co-manager. The proceeds will fund pipeline advancement, clinical trials, regulatory submissions, commercial preparation, and manufacturing scale-up activities. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced a proposed public offering of common shares. The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares.
The offering will be jointly managed by Cantor and LifeSci Capital as book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.
The final terms and size of the offering will be determined at pricing, with completion subject to customary conditions including TSX and Nasdaq listing approvals.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced positive 1-year clinical results from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The trial demonstrated that 67% of patients in Cohort 5 (48mg dose) maintained clinical remission after 12 months.
Key findings include significant tissue health improvements, with patients treated with 4mg per injection showing 47% improvement in grade and 44% in stage at week 36. The drug maintained steady plasma levels through 52 weeks, below typical asthma inhaler levels. Importantly, no serious adverse events or oral/gastrointestinal candidiasis were reported.
The company believes EP-104GI could potentially offer a revolutionary once-yearly treatment option, administered during routine annual endoscopy procedures, presenting a significant advantage over current daily oral steroids or weekly biologics.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q2 2025 financial results and provided updates on its EP-104GI clinical program for Eosinophilic Esophagitis (EoE). The company has initiated the Phase 2b placebo-controlled portion of the RESOLVE trial, with topline data expected in H2 2026. The trial will enroll a minimum of 60 patients across 25 global sites.
Key financial metrics include a net loss of $8.7 million for Q2 2025, compared to $6.1 million in Q2 2024. Cash position stands at $19.8 million as of June 30, 2025, expected to fund operations into Q3 2026. Recent Phase 1b/2a data showed sustained positive treatment outcomes after nine months of therapy, with no serious adverse events reported.
FAQ
What is the current stock price of Eupraxia Pharmac (EPRX)?
What is the market cap of Eupraxia Pharmac (EPRX)?
